CSIMarket Company Name, Ticker, Customers, else..
 
Io Biotech Inc   (NASDAQ: IOBT)
 
Price: $0.0085 $0.00 3.659%
Day's High: $0.009619999676942825 Week Perf: 286.36 %
Day's Low: $ 0.00 30 Day Perf: 112.5 %
Volume (M): 1,179,702 52 Wk High: $ 2.08
Volume (M$): $ 0 52 Wk Avg: $0.52
Open: $0.01 52 Wk Low: $0.00



 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 67
 Employees 19
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -88
 Cash Flow (TTM) (Millions $) -48
 Capital Exp. (TTM) (Millions $) 0

Business Description


Io Biotech Inc is a biotechnology company that focuses on the development of immunotherapies for the treatment of cancer and other diseases. They aim to revolutionize the field of immunotherapy by harnessing the power of the immune system to target and eliminate cancer cells. Io Biotech Inc utilizes cutting-edge technology and innovative strategies to create personalized immunotherapeutic solutions tailored to the individual needs of patients. Through their research and development efforts, they strive to improve patient outcomes and make significant advancements in the field of cancer treatment.


   Company Address: Ole Maaløes Vej 3 Copenhagen N 0
   Company Phone Number: 7070 2980   Stock Exchange / Ticker: NASDAQ IOBT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ADCT        25.71% 
MDGL        1.49% 
MGNX        6.93% 
RYTM   -5.77%    
SDGR        7.24% 
SUPN   -1.89%    
• View Complete Report
   



Clinical Study

Pre-Clinical Insights from IO Biotech Advancements in Therapeutic Cancer Vaccine Candidates Presented at SITC 2025

Published Fri, Nov 7 2025 3:41 PM UTC

At the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC), IO Biotech presented compelling pre-clinical data on its additional therapeutic cancer vaccine candidates. This research highlights the company s commitment to advancing immunotherapeutic approaches in oncology. Alongside this, recent market performance indicators suggest a positive outlook for IO ...
Clinical Study

Phase 3 Trial Results for Cylembio Plus Pembrolizumab in First-Line Advanced Melanoma Treatment Efficacy

Published Mon, Oct 20 2025 7:21 AM UTC

: The Phase 3 trial evaluating the combination of Cylembio and pembrolizumab (KEYTRUDA) for first-line treatment in patients with advanced melanoma reported promising results at the European Society for Medical Oncology (ESMO) Congress 2025. This article will outline the trial s design, patient outcomes, and potential clinical implications for the treatment of advanced mel...
Clinical Study

IO Biotech Celebrates Advanced Melanoma Research Milestone Amidst Financial Liquidity Challenges at ESMO Congress 202...

Published Tue, Sep 23 2025 12:24 PM UTC

IO Biotech Announces Promising Data in Advanced Melanoma at ESMO Congress 2025 Amid Financial Performance Challenges IO Biotech Inc. has made a notable scientific achievement with its recent announcement that a late-breaking abstract on advanced melanoma has been selected for an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2025. This recogni...
Product Service News

Promising Outcomes in Metastatic Lung Cancer IO Biotechs Innovative Vaccine and Keytruda Show Enhanced Efficacy in P...

Published Thu, Nov 7 2024 3:00 PM UTC

In a groundbreaking development for the treatment of metastatic non-small cell lung cancer (NSCLC), IO Biotech has reported positive results from its Phase 2 IOB-022 study, evaluating the efficacy and safety of its off-the-shelf therapeutic cancer vaccine, IO102-IO103, in combination with the well-established immunotherapy agent, Keytruda (pembrolizumab). This innovative the...
Product Service News

Advancements in Immunotherapy Promising Phase 2 Results of IO102-IO103 for First-Line Treatment of Advanced Head and ...

Published Sat, Sep 14 2024 6:30 AM UTC

The field of oncology has seen remarkable advancements over the past decade, particularly in the domain of immunotherapy. One area of significant interest is advanced head and neck cancer (HNC), which often presents a complex challenge due to its unique biological characteristics and the surrounding critical structures. A recent Phase 2 clinical trial conducted by IO Biotec...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 0.62
PEG (TTM) -

Financial Strength Current
Quick Ratio 1.67
Working Capital Ratio 2.01
Leverage Ratio (MRQ) 42.86
Total Debt to Equity 18.29
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.35 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 0.46 $
Book Value 0.01 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -4,649,947
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.